The level of anxiety in women with graves’ disease

Relevance

Thyroid gland (TG) diseases have a leading place among all forms of endocrine pathology. One of the most common distyroid conditions is Graves’ disease (GD), which occurs with the frequency of 23 cases per 100 thousand populations, and recently this indicator has increased.1-4 Different changes in thyroid gland function during GD lead to numerous clinical manifestations because of the nervous system damage. Over the past decades only scattered information about the specific neurological syndromes caused by thyrotoxicosis has been presented. There are possibilities of other changes, such as changes in the level of consciousness (psychomotor agitation, sopor), up to dementia. Thus, the pathology of the neuromuscular system includes myasthenic syndrome in 10-75% of patients, encephalopathy in 70.8-91.5% and polyneuropathy in 0-4.7%.2-3 Based on the above-said, we set the goal: to study the level of anxiety in women with GD depending on the activity of the disease.

Materials and methods

81 women with GD were examined during inpatient treatment in the department of “Thyroid pathology” and at consultative polyclinic of the Republican Specialized Scientific and Practical Medical Center of Endocrinology (RSSPMCE). The average age of the patients was 33.7±7.4 years. According to the functional state of the thyroid gland, women are divided into the following groups: 1-group, patients with GD in the stage of thyrotoxicosis, n=45 women (55.6%). 2-group, patients with GD in the stage of remission of thyrotoxicosis, n=36(44.4%). The control group consisted of 28 healthy women of the same age (mean age 30.5±5.3 years) without thyroid dysfunction. The average duration of the disease in all patients was 3.5±0.8 years. Table 1 Women in-group 1 received thyrostatics (mercazolil or propylthiouracil) in an individually selected dose. In addition to thyrostatics, detoxification, antianemic and, if necessary symptomatic treatment were prescribed. The average dose of thyrostatics was 20-30 mg per day. Treatment with thyrostatics was carried out under the control of free thyroid hormones and TSH levels in blood serum. Group 2 was consisting of women who received conservative treatment for 12-18 months, during this time, the levels of TSH and free T4 were in the normal ranges. After consultation with the endocrinologist and before the beginning of thyreostatic treatment, patients were consulted by a neurologist on the basis of the RSSPMCE. For more detailed study of the neuropsychological status and cognitive impairment Spielberger-Khanin test has been used. Testing using the Spielberger-Khanin method is carried out using two forms: one for measuring indicators of situational anxiety (reactive anxiety, statements No.1-20), and the second for measuring the level of personal anxiety (personal anxiety, statements No. 21-40). In all patients, we have assessed levels of TSH, free T4 (anti-T4), antibodies to TPO in serum by the RIA method using commercial sets of the firm “Immonotech” (Czech Republic) on the basis of RSSPMCE. The regulatory levels of hormones by this method were as following: fT4=11.5-23.0 pmol/L; TSH=0.17-4.05 mUI/L, antibodies to TPO above 12 IU/ml. All patients underwent an ultrasound examination of the thyroid gland with the determination of its volume using an ultrasound scanner “US-SIM-5000 FUCUDA-U2000 (Japan)” equipped with a linear sensor 7.0MHz. The results of the research were inserted into the Microsoft Excel program. Statistical analysis of the results of the study was carried out using the statistical program STATISTICA 6 and Biostat.

Table 1 Spreading of women by groups

| Groups                                      | Number of women | Average age |
|---------------------------------------------|-----------------|-------------|
| 1-group of GD in the stage of thyrotoxicosis| n = 45          | 33.5±6.4    |
| 2-group GD in the stage of remission of thyrotoxicosis | n = 36          |             |
| Control group, healthy women               | n = 28          | 30.5±5.3    |

Results

The average duration of the disease in all patients was 3.8±1.4 years. Estimation of thyroid status by the results of thyroid hormone levels and serum TSH in the patients of the 1st group revealed that the level of fT4 was elevated and the level of TSH was decreased, which corresponded to the thyrotoxicosis. The indicators of fT4 and TSH of blood serum in the 2nd group were within the normal ranges (Figure 1). According to the goal, we evaluated neurological and neuropsychological status, depending on the activity of the disease.
The Spielberger-Khanin test showed a high level of reactive anxiety (RA) is seen in 17 (54.8%) patients with thyrotoxicosis, and a high level of personal anxiety (PA) for 18 (58.1%) patients. In women with GD in the stage of thyrotoxicosis remission, we have seen a low level of RA (14–46.7%) and PA (14–46.7%). In the control group, there was only a low level of RA (4–14.3%) and PA (3–10.7%) (Figure 2). Integral assessment of RA of patients with GD in the stage of thyrotoxicosis was 36.9±11.6 points, PA 39.3±13.7 points. In the group with GD in the stage of remission, thyrotoxicosis RA and PA in total 29.5±12.8 points and 27.4±14.1 points, respectively. In the control group, RA and PA parameters were in total 5.3±3.3 points and 4.3±1.3 points, respectively. The reactive anxiety in patients with GD in the stage of thyrotoxicosis was manifested by a feeling of stiffness and inability to relax (in 48.4%), anxiety (in 51.6%), tension (38.7%), feelings of unrest (19.4%), a sense of anxiety due to palpitation (in 12.9%), attention disorders (in 6.5%). Personal anxiety manifested with tearfulness (in 48.4%), with a feeling of fatigue (51.6%) and doubt in the succeeding of treatment (in 22.6%). In patients with GD in the stage of remission, thyrotoxicosis RA was manifested by anxiety (10.0%), a sense of unrest (in 10.0%), a sense of anxiety due to palpitations (in 13.3%). Personal anxiety manifested with tearfulness (6.7%) and weakness (6.7%).

Conclusion
As a result of the analysis of the obtained data, we can formulate followings:

i. An increase in the level of thyroid hormones leads to a negative effect on the structure of the central nervous system.

ii. Pathological changes in the part of neuropsychological and neurological status are revealed even in patients who do not make active complaints to the neurologist.

iii. The Spielberger-Khanin test showed a high level of RA is seen in 54.8% patients with thyrotoxicosis, and a high level of personal anxiety PA for 58.1% patients. In women with GD in the stage of thyrotoxicosis remission, we have seen a low level of RA 46.7% and PA 46.7%.

iv. Psychoemotional disorders and autonomic disorders prevailed in patients with GD in the stage of thyrotoxicosis, while in the structure of psychoemotional disorders, neurotic-like conditions, confirmed by the results of neuropsychological testing, appeared to the fore.

Acknowledgments
None.

Conflict of interest
The author declares no conflict of interest.

References
1. Abraham NM, Wallin G, Trdisk F, et al. Thyroid associated ophthalmopathy; quality of life, follow-up of patients, randomized to treatment with antithyroid drugs or radiiodine. Eur J Endocrinol. 2010;163(4):651‒657.
2. Bensenor IM, Lotufo PA, Menezes PR, et al. Subclinical hyperthyroidism and dementia: the Sao Paulo Aging & Health Study (SPAHA). BMC Public Health. 2010;10:298‒302.
3. Zaitsev IA, Kirienko VT, Zhidkikh VN, et al. Evaluation of the quality of life in healthy individuals. Visnik morskoi meditsini. 2010;2(48):30‒36.
4. Ismailov SI, Ubaydullaeva NB, Mirzazeva UZ. The quality of women with Graves disease after radioiodine therapy. European Science Review. 2016:49–54.
5. Ismailov SI, Akbutayev AM, Elov AA. Quality of life on patients on the background of therapy with thyroxine and a combination of thyroxine and triiodothyronine after total thyroidectomy due to Graves' disease.
The level of anxiety in women with Graves’ disease

International Endocrinology Journal. 2014;5(61):52–55.

6. Ismailov SI, Ubaidullaeva NB, Nasyrhodzhaev Ya B, et al. Pregnancy and outcomes of labor in women with diffuse toxic goiter after radioiodine therapy. *Infection, immunity, and pharmacology*. 2014;5:66–72.

7. Kim JM, Stewart R, Kim SY, et al. Thyroid stimulating hormone, cognitive impairment and depression in an older Korean population. *Psychiatry Investig*. 2010;7(4):264–269.

8. Cramon P, Winther K, Watt T, et al. Quality-of-Life Impairments Persist Six Months After Treatment of Graves’ Hyperthyroidism and Toxic Nodular Goiter. *A Prospective Cohort Study Thyroid*. 2016;26(8):1010–1018.

9. Placidia GPA, Boldrinia M, Patronellia A, et al. Prevalence of Psychiatric Disorders in Thyroid Diseased Patients. *Neuropsychobiology*. 1998;38(4):222–225.

10. Ritchie M, Yeap BB. Thyroid hormone: Influences on mood and cognition in adults. *Maturitas*. 2015;81(2):266–275.

11. Vadiveloo T, Donnan PT, Cochrane L, et al. The Thyroid Epidemiology, Audit, and Research Study (TEARS): morbidity in patients with endogenous subclinical hyperthyroidism. *J Clin Endocrinol Metab*. 2011;96(5):1344–1351.

12. Shah MS, Davies TF, Stagmaro Green A. The thyroid during pregnancy: a physiological and pathological stress test. *Minerva Endocrinol*. 2003;28(3):233–245.